ArticleTranslational cancer research2024
Development of a prediction model for the association between thyroid dysfunction and breast cancer.
Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sleep factors and risk of thyroid cancer, nodules and dysfunction: Mendelian randomization study.Gland surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid dysfunction is associated with the risk of benign and malignant breast tumors, but currently there is a lack of model studies to demonstrate the predictive role of thyroid dysfunction in benign and malignant breast tumors. This study aims to establish a model for predicting the association between thyroid dysfunction and breast cancer. Methods: This retrospective study enrolled breast tumor patients from the Affiliated Tumor Hospital of Xinjiang Medical University from 2015 to 2019. Their baseline data and laboratory data were collected. Python was used for data processing and analysis. Data preparation, feature selection, model construction, and model evaluation were conducted. We utilized the classification probabilities generated by the model as scores and further conducted a least absolute shrinkage and selection operator analysis. Results: Analysis of the laboratory data revealed statistically significant differences in thyroid-stimulating hormone, thyroxine, free thyroxine, free triiodothyronine, and thyronine levels between patients with benign and malignant tumors. Based on age, ethnicity, thyroid function, and estrogen levels, the predictive model for breast tumor malignancy indicated that the factors with the greatest importance ranking were age > follicle-stimulating hormone > luteinizing hormone > prolactin > thyroxine > testosterone > ethnicity. The model showed an accuracy rate of 83.70%, precision of 90.69%, sensitivity of 84.74%, and specificity of 81.50%. The area under the receiver operating characteristic curve was 0.9012, close to 1, indicating good predictive performance of the model. Conclusions: The predictive model based on factors such as age, ethnicity, thyroid function, and estrogen levels performs well in predicting the occurrence and development of benign and malignant breast tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.